Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06334432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 8 of 8 sitesv4 Show 1 more changeShow less
    • Site details revised at 8 of 8 sites
  2. Study sites: 6 to 8v3
  3. Study sites: 3 to 6 Start date changed from estimate of Mar 2024 to Mar 14, 2024v2 Show 1 more changeShow less
    • Start date changed from estimate of Mar 2024 to Mar 14, 2024
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Nuvation Bio
10 trials monitored
See all monitored trials
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
Pancreatic Cancer
1,639 trials monitored
See 91 trials at risk
and 1 more disease
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Trial Details
NCT Number NCT06334432
Lead Sponsor Nuvation Bio Inc.
Conditions Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Enrollment 466 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov